🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to scientists.

A Global Health Concern

Gonorrhoea infections are on the rise worldwide, with figures suggesting more than 82 million instances each year. Especially elevated rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely step in the face of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted available drugs at this time.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has designated it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Therapies Receive Clearance

One new antibiotic, marketed under the name a brand name, was approved by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts believe that specific application of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the pharmaceutical company GSK, also received approval in close succession. This treatment, which is employed against UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a new, not-for-profit approach for drug creation. The charitable organization GARDP worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This milestone signifies a major breakthrough in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Testing Results and Global Access

According to results detailed in a major medical journal, zoliflodacin successfully treated the vast majority of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which combines an injection and a pill. The study involved nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the ability to make available and distribute the drug in a wide range of developing nations.

Doctors on the front lines have expressed hope. Access to a single-dose, oral treatment of this kind is hailed as a "critical tool" for public health efforts. This is considered essential to reduce the burden of the disease for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.